Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Perfosfamide is a synthetic oxazaphosphorine alkylating agent and a derivative of cyclophosphamide. Unlike its parent compound, perfosfamide is pre-activated and does not require hepatic metabolism by cytochrome P450 enzymes to exert its cytotoxic effects. It spontaneously degrades in aqueous solution to form 4-hydroxycyclophosphamide, which then tautomerizes to aldophosphamide and eventually yields the active cytotoxic metabolite, phosphoramide mustard. This metabolite forms DNA cross-links, primarily at the N-7 position of guanine, leading to DNA strand breakage, inhibition of DNA replication, and apoptosis. Perfosfamide has been primarily utilized in ex vivo settings for purging autologous bone marrow or peripheral blood stem cell grafts to eliminate contaminating malignant cells, such as those in acute myeloid leukemia or non-Hodgkin lymphoma, before re-infusion into the patient.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on perfosfamide.